Baidu
map

NICE:建议将Kisqali(ribociclib)与氟维司群联用,用于治疗局部晚期或转移性乳腺癌

2021-02-26 Allan MedSci原创

在欧洲,乳腺癌是女性中最常见的癌症,也是西班牙裔女性中最常见的死亡原因,是其他种族女性中第二常见的死亡原因(仅次于肺癌)。

在欧洲,乳腺癌是女性中最常见的癌症,也是西班牙裔女性中最常见的死亡原因,是其他种族女性中第二常见的死亡原因(仅次于肺癌)。

英国国家健康与护理卓越研究所(NICE)建议在某些晚期乳腺癌患者中常规使用诺华的Kisqali。NICE的指南草案建议将Kisqali(ribociclib)与氟维司群联用,用于治疗激素受体阳性和人表皮生长因子受体2(HER2)阴性的局部晚期或转移性乳腺癌。Kisqali是一种细胞周期蛋白依赖性激酶4和6(CDK4 / 6)抑制剂。

自2019年以来,Kisqali已通过癌症药物基金会(CDF)提供给患者使用,同时收集了更多证据来解决有关该药物可延长多少总生存期及其成本效益的不确定性。NICE在一份声明中说,新证据表明,与仅使用氟维司群相比,氟维司群联合Kisqali治疗能够显著延长乳腺癌患者的寿命。

根据有关常规NHS资金的建议,现在可以对多达3,300例患者使用Kisqali。

 

原始出处:

http://www.pharmatimes.com/news/nice_recommends_routine_funding_for_novartis_kisqali_1364227

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1931383, encodeId=345f19313837a, content=<a href='/topic/show?id=de6c10511e3' target=_blank style='color:#2F92EE;'>#Kisqali#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10511, encryptionId=de6c10511e3, topicName=Kisqali)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jul 15 15:09:33 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650791, encodeId=209a1650e917b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Sun Oct 31 15:09:33 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289103, encodeId=dabb12891032a, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386718, encodeId=77c41386e18ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406027, encodeId=4eb8140602e3b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488586, encodeId=3d1014885865f, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=)]
    2021-07-15 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1931383, encodeId=345f19313837a, content=<a href='/topic/show?id=de6c10511e3' target=_blank style='color:#2F92EE;'>#Kisqali#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10511, encryptionId=de6c10511e3, topicName=Kisqali)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jul 15 15:09:33 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650791, encodeId=209a1650e917b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Sun Oct 31 15:09:33 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289103, encodeId=dabb12891032a, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386718, encodeId=77c41386e18ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406027, encodeId=4eb8140602e3b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488586, encodeId=3d1014885865f, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1931383, encodeId=345f19313837a, content=<a href='/topic/show?id=de6c10511e3' target=_blank style='color:#2F92EE;'>#Kisqali#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10511, encryptionId=de6c10511e3, topicName=Kisqali)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jul 15 15:09:33 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650791, encodeId=209a1650e917b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Sun Oct 31 15:09:33 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289103, encodeId=dabb12891032a, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386718, encodeId=77c41386e18ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406027, encodeId=4eb8140602e3b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488586, encodeId=3d1014885865f, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=)]
    2021-02-28 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=1931383, encodeId=345f19313837a, content=<a href='/topic/show?id=de6c10511e3' target=_blank style='color:#2F92EE;'>#Kisqali#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10511, encryptionId=de6c10511e3, topicName=Kisqali)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jul 15 15:09:33 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650791, encodeId=209a1650e917b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Sun Oct 31 15:09:33 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289103, encodeId=dabb12891032a, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386718, encodeId=77c41386e18ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406027, encodeId=4eb8140602e3b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488586, encodeId=3d1014885865f, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1931383, encodeId=345f19313837a, content=<a href='/topic/show?id=de6c10511e3' target=_blank style='color:#2F92EE;'>#Kisqali#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10511, encryptionId=de6c10511e3, topicName=Kisqali)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jul 15 15:09:33 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650791, encodeId=209a1650e917b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Sun Oct 31 15:09:33 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289103, encodeId=dabb12891032a, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386718, encodeId=77c41386e18ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406027, encodeId=4eb8140602e3b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488586, encodeId=3d1014885865f, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=)]
    2021-02-28 chg122
  6. [GetPortalCommentsPageByObjectIdResponse(id=1931383, encodeId=345f19313837a, content=<a href='/topic/show?id=de6c10511e3' target=_blank style='color:#2F92EE;'>#Kisqali#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10511, encryptionId=de6c10511e3, topicName=Kisqali)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jul 15 15:09:33 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650791, encodeId=209a1650e917b, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47614, encryptionId=ffae4e614b6, topicName=局部晚期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=901d24099859, createdName=yhy100208, createdTime=Sun Oct 31 15:09:33 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289103, encodeId=dabb12891032a, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386718, encodeId=77c41386e18ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406027, encodeId=4eb8140602e3b, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488586, encodeId=3d1014885865f, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15457, encryptionId=bc7a1545e44, topicName=ribociclib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f558440263, createdName=般若傻瓜, createdTime=Sun Feb 28 11:09:33 CST 2021, time=2021-02-28, status=1, ipAttribution=)]

相关资讯

Lancet oncol:abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期

接受过两种或两种以上的晚期疾病治疗的HER2阳性乳腺癌患者,有效的治疗方案很少。本研究(monarcHER试验)旨在评估abemaciclib+曲妥珠单抗联合(或不联合)氟维司群疗法和标准化疗联合曲妥

Clin Cancer Res:Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌

HR+HER2-晚期乳腺癌(ABC)患者对内分泌疗法耐药较常见,CDK4/6和PI3K通路的双重抑制或可延缓该类患者耐药性的发展。本研究旨在评估包含CDK4/6抑制剂瑞博西尼(ribociclib)的

乳腺癌病例:辅助内分泌原发耐药患者晚期一线化疗后氟维司群维持治疗的重要性

乳腺癌是女性恶性肿瘤发病率最高的疾病,是威胁女性“健康”的杀手,乳腺癌防治受到广泛的关注。激素受体阳性乳腺癌占乳腺癌中70% ~ 80%,术后患者需要接受5 ~ 10年的内分泌治疗,多数患者能够获得较好的预后,但即使如此,仍有部分患者出现复发转移。本文分享一例绝经前激素阳性乳腺癌患者的诊疗历程,探讨这类患者的诊疗思路。

Lancet Oncol:Capivasertib联合氟维司群可显著延长晚期乳腺癌患者的无进展存活期

Capivasertib(AZD5363)是一种对丝氨酸/苏氨酸激酶AKT的所有三种亚型都有效的选择性口服抑制剂。FAKTION研究评估了将Capivasertib加入氟维司群是否可提高芳香化酶抑制剂抵抗性晚期乳腺癌患者的无进展存活期。FAKTION研究是一项随机的、双盲的、安慰剂为对照的2期试验,招募年满18岁的绝经女性,EOCG表现状态0-2分、雌激素受体阳性、HER2阳性、转移或局部晚期、不

NEJM:Ribociclib+氟维司群可改善晚期乳腺癌患者生存期

研究认为,在激素受体阳性、HER 2阴性的晚期乳腺癌患者中,Ribociclib+氟维司群可显著提高患者的总体生存率

Ann Oncol:Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效

通过PIK3CA突变激活磷脂酰肌醇-3-激酶(PI3K)通路在激素受体阳性(HR+)、人表皮生长因子受体-2阴性(HER2-)的晚期乳腺癌(ABC)中的发生率约28%-46%,与患者预后不良有关

拓展阅读

聚焦前沿热点,共创未来发展——第四届天津国际乳腺癌大会成功举办

12月20日,由中国抗癌协会主办,天津医科大学肿瘤医院、国家恶性肿瘤临床医学研究中心共同承办的第四届天津国际乳腺癌大会在滨海新区召开。

【中西合璧】针刺对慢性神经性疼痛的调节及其与脑功能特性的关系—针刺对神经性疼痛的影响

在标准三联止吐治疗的基础上加入真电针,可显著提高接受HEC治疗的乳腺癌患者CINV治疗的疗效。

HER2阳性乳腺癌按FISH结果细分,靶向治疗获益分层

这些发现提供了有价值的关于不同 HER2 FISH 阳性亚组的临床病理学见解,可能为未来解读 HER2 FISH 结果的标准提供信息。

会议预告丨2024天津国际乳腺癌大会(12.18-12.21)

天津国际乳腺癌大会将于2024年12月18日至21日在历史悠久而又充满活力的滨海之都天津盛大召开。本次大会以“健康同行创未来,携手同彩映前程”为主题,旨在汇聚全球前瞻医学智慧,共绘乳腺肿瘤防治新篇章。

无进展生存期近乎翻倍!NEJM:新药有望延缓乳腺癌患者病情进展

NEJM 发表研究显示,imlunestrant 有望治疗部分复发性乳腺癌。试验表明其对有 ESR1 突变患者能延长 PFS,联合阿贝西利效果更好,安全性也不错。

西安电子科技大学夏玉琼团队《Materials Today Bio》:开发高度稳定和近红外响应的相变材料靶向酶递送用于癌症治疗

西安电子科大夏玉琼团队开发 GCI@RPCM 纳米平台,以实现 NIR 触发的酶动力治疗乳腺癌,介绍其成果发表情况、平台组成、工作机制、性能及优势,给出原文链接。

Baidu
map
Baidu
map
Baidu
map